eFFECTOR Translates $38.6m Into Five Cancer Clinical Trials
Executive Summary
The firm's $38.6m in Series C cash will fund additional clinical trials for lead translation regulator eFT508, support the first human trial for eFT226 and advance a third program into preclinical studies.
You may also be interested in...
Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
Effector Selects Lead Cancer Compound, Looks Ahead To Combo Regimens
Leading the way in translation regulation, biotech moves its first candidate into clinical development in solid tumors, but plans quick move also into lymphoma.
OrbiMed Closes A $950m Fund As Biotech VC Surge Continues
The health care-focused venture capital firm OrbiMed has raised its largest VC fund to date totaling $950m and if prior investment patterns are repeated as much as $760m of that could be invested in companies focused on the development of drugs or gene therapies.